Impact of Sapien 3 Balloon-Expandable Versus Evolut R Self-Expandable Transcatheter Aortic Valve Implantation in Patients with Aortic Stenosis: Data from a Nationwide Analysis.
Background: Two competing Transcatheter aortic valve replacement (TAVR) technologies are currently available. Head-to-head comparisons of the relative performances of these two devices have been published. However, long-term clinical outcome evaluation remains limited by the number of patients analyzed, particularly for recent generation devices. Methods: Based on the French administrative hospital-discharge database, the study collected information for all consecutive patients treated with TAVR device commercialized in France between 2014 and 2018. Propensity score matching was used for the analysis of outcomes during follow-up. The objective of this study was to analyze the outcomes of TAVR according to Sapien 3 balloon-expandable (BE) versus Evolut R self-expanding (SE) TAVR technology at a nationwide level in France. Results: A total of 31 113 patients treated with either Sapien 3 BE or Evolut R SE TAVR were found in the database. After matching on baseline characteristics, 20 918 patients were analyzed (10 459 in each group with BE or SE valves). During follow-up (mean [SD] 358 [384], median [IQR] 232 [10-599] days), BE TAVR was associated with lower yearly incidence of all-cause death (relative risk [RR] 0.88, corrected p=0.005), cardiovascular death (RR 0.82, corrected p=0.002) and rehospitalization for heart failure (RR 0.84, corrected p<0.0001). BE TAVR was also associated with lower rates of pacemaker implantation after the procedure (RR 0.72, corrected p<0.0001). Conclusions: Based on the largest cohort available, we observed that Sapien 3 BE valves were associated with lower rates of all-cause death, cardiovascular death, rehospitalization for heart failure, and pacemaker implantation after a TAVR procedure.